{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T22:29:00Z","timestamp":1776464940451,"version":"3.51.2"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T00:00:00Z","timestamp":1585958400000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["FCT-PTDC\/MEC-MHEM\/30315\/2017"],"award-info":[{"award-number":["FCT-PTDC\/MEC-MHEM\/30315\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple myeloma (MM) is a challenging, progressive, and highly heterogeneous hematological malignancy. MM is characterized by multifocal proliferation of neoplastic plasma cells in the bone marrow (BM) and sometimes in extramedullary organs. Despite the availability of novel drugs and the longer median overall survival, some patients survive more than 10\u00a0years while others die rapidly. This heterogeneity is mainly driven by biological characteristics of MM cells, including genetic abnormalities. Disease progressions are mainly due to the inability of drugs to overcome refractory disease and inevitable drug-resistant relapse. In clinical practice, a bone marrow biopsy, mostly performed in one site, is still used to access the genetics of MM. However, BM biopsy use is limited by its invasive nature and by often not accurately reflecting the mutational profile of MM. Recent insights into the genetic landscape of MM provide a valuable opportunity to implement precision medicine approaches aiming to enable better patient profiling and selection of targeted therapies. In this review, we explore the use of the emerging field of liquid biopsies in myeloma patients considering current unmet medical needs, such as assessing the dynamic mutational landscape of myeloma, early predictors of treatment response, and a less invasive response monitoring.<\/jats:p>","DOI":"10.1007\/s00109-020-01897-9","type":"journal-article","created":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T02:02:26Z","timestamp":1585965746000},"page":"513-525","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Liquid biopsies for multiple myeloma in a time of precision medicine"],"prefix":"10.1007","volume":"98","author":[{"given":"Bruna","family":"Ferreira","sequence":"first","affiliation":[]},{"given":"Joana","family":"Caetano","sequence":"additional","affiliation":[]},{"given":"Filipa","family":"Barahona","sequence":"additional","affiliation":[]},{"given":"Raquel","family":"Lopes","sequence":"additional","affiliation":[]},{"given":"Emilie","family":"Carneiro","sequence":"additional","affiliation":[]},{"given":"Bruno","family":"Costa-Silva","sequence":"additional","affiliation":[]},{"given":"Cristina","family":"Jo\u00e3o","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,4,4]]},"reference":[{"key":"1897_CR1","doi-asserted-by":"crossref","unstructured":"Landgren O, Kyle R, Pfeiffer RM, Katzmann J, Caporaso NE, Richard B, et al (2014) Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. 113(22):5412\u20137","DOI":"10.1182\/blood-2008-12-194241"},{"key":"1897_CR2","doi-asserted-by":"crossref","unstructured":"Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM (2009) A monoclonal gammopathy precedes multiple myeloma in most patients. Clin Trialsand Obs 113(22):5418\u20135422","DOI":"10.1182\/blood-2008-12-195008"},{"key":"1897_CR3","unstructured":"Jo\u00e3o C, Coelho I, Costa C, Esteves S, Lucio P. Efficacy and safety of lenalidomide in relapse\/refractory multiple myeloma\u2014real life experience of a tertiary cancer center"},{"key":"1897_CR4","doi-asserted-by":"crossref","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia [Internet]. 28:1122\u20138. Available from: www.nature.com\/leu","DOI":"10.1038\/leu.2013.313"},{"issue":"15","key":"1897_CR5","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"P Sonneveld","year":"2005","unstructured":"Sonneveld P, Westin J, Shimizu K, Morgan G, Greipp PR, Durie BGM et al (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):3412\u20133420","journal-title":"J Clin Oncol"},{"issue":"26","key":"1897_CR6","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L et al (2015 Aug) Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 33(26):2863\u20132869","journal-title":"J Clin Oncol"},{"issue":"1","key":"1897_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/ejh.12546","volume":"96","author":"H Nahi","year":"2016","unstructured":"Nahi H, V\u00e5tsveen TK, Lund J, Heeg BMS, Preiss B, Alici E, M\u00f8ller MB, Wader KF, M\u00f8ller HE, Gr\u00f8seth LA, \u00d8stergaard B, Dai HY, Holmberg E, Gahrton G, Waage A, Abildgaard N (2016 Jan 1) Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21. Eur J Haematol 96(1):46\u201354","journal-title":"Eur J Haematol"},{"issue":"24","key":"1897_CR8","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1182\/blood-2015-03-632075","volume":"125","author":"JR Sawyer","year":"2015","unstructured":"Sawyer JR, Tian E, Heuck CJ, Johann DJ, Epstein J, Swanson CM, Lukacs JL, Binz RL, Johnson M, Sammartino G, Zangari M, Davies FE, van Rhee F, Morgan GJ, Barlogie B (2015 Jun 11) Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma. Blood. 125(24):3756\u20133759","journal-title":"Blood."},{"key":"1897_CR9","doi-asserted-by":"crossref","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. (2016) Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Vol. 127, Blood. American Society of Hematology; p. 2955\u201362","DOI":"10.1182\/blood-2016-01-631200"},{"key":"1897_CR10","doi-asserted-by":"crossref","unstructured":"Zamagni E, Tacchetti P, Cavo M (2019) Imaging in multiple myeloma: how? When? Blood. 133(7):644 LP \u2013 651","DOI":"10.1182\/blood-2018-08-825356"},{"issue":"1","key":"1897_CR11","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","volume":"8","author":"L Rasche","year":"2017","unstructured":"Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C et al (2017 Dec) Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun 8(1):268","journal-title":"Nat Commun"},{"key":"1897_CR12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","volume":"14","author":"S Manier","year":"2016","unstructured":"Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM (2016 Aug) Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol 14:100","journal-title":"Nat Rev Clin Oncol"},{"key":"1897_CR13","doi-asserted-by":"crossref","unstructured":"Morgan GJ, Walker BA, Davies FE (2012) The genetic architecture of multiple myeloma. Vol. 12, Nature Reviews Cancer. p. 335\u201348","DOI":"10.1038\/nrc3257"},{"issue":"1","key":"1897_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/10428194.2017.1335398","volume":"59","author":"T Sun","year":"2018","unstructured":"Sun T, Wang S, Sun H, Wen J, An G, Li J (2018 Jan) Improved survival in multiple myeloma, with a diminishing racial gap and a widening socioeconomic status gap over three decades. Leuk Lymphoma 59(1):49\u201358","journal-title":"Leuk Lymphoma"},{"key":"1897_CR15","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garc\u00eda-S\u00e1nchez O, B\u00f6ttcher S et al (2017 Jan) Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 31:2094","journal-title":"Leukemia."},{"key":"1897_CR16","doi-asserted-by":"crossref","unstructured":"Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien M-L, et al. (2018) Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 132(23):2456 LP \u2013 2464","DOI":"10.1182\/blood-2018-06-858613"},{"issue":"8","key":"1897_CR17","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blad\u00e9 J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H (2016 Aug) International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013e346","journal-title":"Lancet Oncol"},{"issue":"1","key":"1897_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","volume":"3","author":"NC Munshi","year":"2017","unstructured":"Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, Sherrington P, Samur MK, Georgieva A, Anderson KC, Gregory WM (2017 Jan) Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma. JAMA Oncol 3(1):28\u201335","journal-title":"JAMA Oncol"},{"issue":"3","key":"1897_CR19","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.tips.2019.01.006","volume":"40","author":"G De Rubis","year":"2019","unstructured":"De Rubis G, Rajeev Krishnan S, Bebawy M (2019 Mar) Liquid biopsies in cancer diagnosis, monitoring, and prognosis. Trends Pharmacol Sci 40(3):172\u2013186","journal-title":"Trends Pharmacol Sci"},{"key":"1897_CR20","doi-asserted-by":"crossref","unstructured":"Kwapisz D (2017) The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer? Ann Transl Med Vol 5, No 3 Ann Transl Med (Focus \u201cTreatment Hepat B\u201d) 2017","DOI":"10.21037\/atm.2017.01.32"},{"key":"1897_CR21","doi-asserted-by":"crossref","unstructured":"Wills B, Gorse E, Lee V. (2018) Role of liquid biopsies in colorectal cancer. Curr Probl Cancer [Internet]. [cited 2019 Sep 12];42(6):593\u2013600. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30268335","DOI":"10.1016\/j.currproblcancer.2018.08.004"},{"issue":"9","key":"1897_CR22","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1200\/JCO.2016.70.6705","volume":"35","author":"S Robiou du Pont","year":"2017","unstructured":"Robiou du Pont S, Cleynen A, Fontan C, Attal M, Munshi N, Corre J, Avet-Loiseau H (2017 Mar) Genomics of multiple myeloma. J Clin Oncol 35(9):963\u2013967","journal-title":"J Clin Oncol"},{"key":"1897_CR23","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1038\/ncomms3997","volume":"5","author":"N Bolli","year":"2014","unstructured":"Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I et al (2014 Jan) Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 5:2997","journal-title":"Nat Commun"},{"issue":"33","key":"1897_CR24","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","volume":"33","author":"BA Walker","year":"2015","unstructured":"Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, Proszek PZ, Johnson DC, Kaiser MF, Melchor L, Aronson LI, Scales M, Pawlyn C, Mirabella F, Jones JR, Brioli A, Mikulasova A, Cairns DA, Gregory WM, Quartilho A, Drayson MT, Russell N, Cook G, Jackson GH, Leleu X, Davies FE, Morgan GJ (2015 Aug) Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol 33(33):3911\u20133920","journal-title":"J Clin Oncol"},{"key":"1897_CR25","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/leu.2013.199","volume":"28","author":"BA Walker","year":"2013","unstructured":"Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF et al (2013 Jul) Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 28:384","journal-title":"Leukemia."},{"key":"1897_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.72","volume":"6","author":"N Bolli","year":"2016","unstructured":"Bolli N, Li Y, Sathiaseelan V, Raine K, Jones D, Ganly P et al (2016) A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. Blood Cancer J 6:e467","journal-title":"Blood Cancer J"},{"key":"1897_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","volume":"471","author":"MA Chapman","year":"2011","unstructured":"Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC et al (2011 Mar) Initial genome sequencing and analysis of multiple myeloma. Nature. 471:467","journal-title":"Nature."},{"issue":"1","key":"1897_CR28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"J Gould","year":"2014","unstructured":"Gould J, Vij R, Fonseca R, Hofmeister CC, Perkins LM, Kumar S et al (2014) Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25(1):91\u2013101","journal-title":"Cancer Cell"},{"issue":"11","key":"1897_CR29","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1038\/s41375-018-0103-3","volume":"32","author":"PH Hoang","year":"2018","unstructured":"Hoang PH, Dobbins SE, Cornish AJ, Chubb D, Law PJ, Kaiser M, Houlston RS (2018) Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms. Leukemia. 32(11):2459\u20132470","journal-title":"Leukemia."},{"key":"1897_CR30","doi-asserted-by":"crossref","unstructured":"Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, et al. (2012) Clonal competition with alternating dominance in multiple myeloma. Blood. ;120(5):1067 LP \u2013 1076","DOI":"10.1182\/blood-2012-01-405985"},{"key":"1897_CR31","doi-asserted-by":"crossref","unstructured":"Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, et al. (2016) Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 128(13):1735 LP \u2013 1744","DOI":"10.1182\/blood-2016-06-723007"},{"key":"1897_CR32","doi-asserted-by":"crossref","unstructured":"Egan JB, Shi C-X, Tembe W, Christoforides A, Kurdoglu A, Sinari S, et al. 2012 Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. Aug;120(5):1060 LP \u2013 1066","DOI":"10.1182\/blood-2012-01-405977"},{"key":"1897_CR33","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1038\/leu.2014.13","volume":"28","author":"L Melchor","year":"2014","unstructured":"Melchor L, Brioli A, Wardell CP, Murison A, Potter NE, Kaiser MF et al (2014 Jan) Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia. 28:1705","journal-title":"Leukemia."},{"issue":"12","key":"1897_CR34","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1038\/s41375-018-0153-6","volume":"32","author":"J Corre","year":"2018","unstructured":"Corre J, Cleynen A, Robiou du Pont S, Buisson L, Bolli N, Attal M et al (2018) Multiple myeloma clonal evolution in homogeneously treated patients. Leukemia. 32(12):2636\u20132647","journal-title":"Leukemia."},{"issue":"1","key":"1897_CR35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, Sougnez C, Knoechel B, Gould J, Saksena G, Cibulskis K, McKenna A, Chapman MA, Straussman R, Levy J, Perkins LM, Keats JJ, Schumacher SE, Rosenberg M, Multiple Myeloma Research Consortium, Getz G, Golub TR (2014 Jan) Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25(1):91\u2013101","journal-title":"Cancer Cell"},{"key":"1897_CR36","doi-asserted-by":"crossref","unstructured":"Raab MS, Lehners N, Xu J, Ho AD, Schirmacher P, Goldschmidt H, et al. (2016) Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition. Blood. 127(17):2155 LP \u2013 2157","DOI":"10.1182\/blood-2015-12-686782"},{"issue":"8","key":"1897_CR37","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMoa1502309","volume":"373","author":"DM Hyman","year":"2015","unstructured":"Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay J-Y, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J (2015) Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373(8):726\u2013736","journal-title":"N Engl J Med"},{"issue":"2","key":"1897_CR38","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1016\/j.clml.2013.12.003","volume":"14","author":"OL Bohn","year":"2014","unstructured":"Bohn OL, Hsu K, Hyman DM, Pignataro DS, Giralt S, Teruya-Feldstein J (2014 Apr) BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation. Clin Lymphoma, Myeloma Leuk 14(2):e65\u2013e68","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"key":"1897_CR39","doi-asserted-by":"crossref","unstructured":"Wu J, Ross J, Peale F V, Shaughnessy JD, Van Laar RK, Morgan GJ, et al. (2016) A Favorable BCL-2 Family expression profile may explain the increased susceptibility of the t(11;14) multiple myeloma subgroup to single agent venetoclax. Blood. ;128(22):5613 LP \u2013 5613","DOI":"10.1182\/blood.V128.22.5613.5613"},{"key":"1897_CR40","doi-asserted-by":"crossref","unstructured":"Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, et al. (2017) Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood.;130(22):2401 LP \u2013 2409","DOI":"10.1182\/blood-2017-06-788786"},{"key":"1897_CR41","unstructured":"Kaufman JL, Gasparetto CJ, Mikhael J, Moreau P, Touzeau C, Vij R, et al. (2017) Phase 1 study of venetoclax in combination with dexamethasone as targeted therapy for t(11;14) relapsed\/refractory multiple myeloma. Blood. 130(Suppl 1):3131 LP \u2013 3131"},{"key":"1897_CR42","doi-asserted-by":"crossref","unstructured":"Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, et al. (2017) Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/ refractory MM. Blood. blood-2017-06-788323","DOI":"10.1182\/blood-2017-06-788323"},{"key":"1897_CR43","doi-asserted-by":"crossref","unstructured":"Costa LJ, Stadtmauer EA, Morgan G, Monohan G, Kovacsovics T, Burwick N, et al. (2018) Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma. Blood. 132(Suppl 1):303 LP \u2013 303","DOI":"10.1182\/blood-2018-99-117026"},{"issue":"2","key":"1897_CR44","doi-asserted-by":"publisher","first-page":"44","DOI":"10.4103\/2394-4722.158803","volume":"1","author":"P Potdar","year":"2015","unstructured":"Potdar P, Lotey N (2015) Role of circulating tumor cells in future diagnosis and therapy of cancer. J Cancer Metastasis Treat 1(2):44","journal-title":"J Cancer Metastasis Treat"},{"key":"1897_CR45","doi-asserted-by":"crossref","unstructured":"Ghobrial IM. Myeloma as a model for the process of metastasis: implications for therapy. Blood [Internet]. 2012 Jul 5 [cited 2019 Aug 19];120(1):20\u201330. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22535658","DOI":"10.1182\/blood-2012-01-379024"},{"issue":"1\u20132","key":"1897_CR46","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.cell.2011.11.025","volume":"148","author":"AD Rhim","year":"2012","unstructured":"Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F et al (2012) EMT and dissemination precede pancreatic tumor formation. Cell. 148(1\u20132):349\u2013361","journal-title":"Cell."},{"issue":"6","key":"1897_CR47","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/1758834010378414","volume":"2","author":"MG Krebs","year":"2010","unstructured":"Krebs MG, Hou J-M, Ward TH, Blackhall FH, Dive C (2010) Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther Adv Med Oncol 2(6):351\u2013365","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"1897_CR48","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/PAP.0000000000000217","volume":"26","author":"KE Sundling","year":"2019","unstructured":"Sundling KE, Lowe AC (2019) Circulating tumor cells: overview and opportunities in cytology. Adv Anat Pathol 26(1):56\u201363","journal-title":"Adv Anat Pathol"},{"issue":"3","key":"1897_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrclinonc.2013.253","volume":"11","author":"MG Krebs","year":"2014","unstructured":"Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C (2014) Molecular analysis of circulating tumour cells \u2014 biology and biomarkers. Nat Rev Clin Oncol 11(3):1\u201316","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"1897_CR50","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ymeth.2010.01.027","volume":"50","author":"M Alunni-Fabbroni","year":"2010","unstructured":"Alunni-Fabbroni M, Sandri MT (2010) Circulating tumour cells in clinical practice: methods of detection and possible characterization. Methods. 50(4):289\u2013297","journal-title":"Methods."},{"key":"1897_CR51","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/nrclinonc.2009.44","volume":"6","author":"K Pantel","year":"2009","unstructured":"Pantel K, Alix-Panabi\u00e8res C, Riethdorf S (2009) Cancer micrometastases. Nat Rev Clin Oncol 6:339\u2013351","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"1897_CR52","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.canlet.2006.12.014","volume":"253","author":"P Paterlini-Brechot","year":"2007","unstructured":"Paterlini-Brechot P, Benali NL (2007) Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 253(2):180\u2013204","journal-title":"Cancer Lett"},{"key":"1897_CR53","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/bjc.2011.294","volume":"105","author":"F Farace","year":"2011","unstructured":"Farace F, Massard C, Vimond N, Drusch F, Jacques N, Billiot F et al (2011 Aug) A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer 105:847","journal-title":"Br J Cancer"},{"key":"1897_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2010\/617421","volume":"2010","author":"MC Miller","year":"2010","unstructured":"Miller MC, Doyle GV, Terstappen LWMM (2010) Significance of circulating tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer. J Oncol 2010:1\u20138","journal-title":"J Oncol"},{"issue":"8","key":"1897_CR55","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJMoa040766","volume":"351","author":"M Cristofanilli","year":"2004","unstructured":"Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8):781\u2013791","journal-title":"N Engl J Med"},{"issue":"19","key":"1897_CR56","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1200\/JCO.2007.15.8923","volume":"26","author":"SJ Cohen","year":"2008","unstructured":"Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ (2008 Jul) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26(19):3213\u20133221","journal-title":"J Clin Oncol"},{"key":"1897_CR57","doi-asserted-by":"crossref","unstructured":"de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 14(19):6302 LP \u2013 6309","DOI":"10.1158\/1078-0432.CCR-08-0872"},{"issue":"8","key":"1897_CR58","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00432-011-0988-y","volume":"137","author":"Y-F Sun","year":"2011","unstructured":"Sun Y-F, Yang X-R, Zhou J, Qiu S-J, Fan J, Xu Y (2011 Jun) Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. J Cancer Res Clin Oncol 137(8):1151\u20131173","journal-title":"J Cancer Res Clin Oncol"},{"key":"1897_CR59","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/bjh.15003","volume":"180","author":"B Foulk","year":"2018","unstructured":"Foulk B, Schaffer M, Gross S, Rao C, Smirnov D, Connelly MC et al (2018) Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders. Br J Hematol 180:71\u201381","journal-title":"Br J Hematol"},{"issue":"11","key":"1897_CR60","first-page":"1","volume":"5","author":"L Zhang","year":"2016","unstructured":"Zhang L, Beasley S, Prigozhina NL, Higgins R, Ikeda S, Lee FY et al (2016) Detection and characterization of circulating tumour cells in multiple myeloma. J Circ Biomarkers 5(11):1\u20138","journal-title":"J Circ Biomarkers"},{"key":"1897_CR61","doi-asserted-by":"crossref","unstructured":"Garc\u00e9s JJ, \u0160im\u00ed\u010dek M, Vicari M, Brozova L, Burgos L, Bezd\u011bkov\u00e1 R, et al. (2019) Transcriptomic profiling of circulating tumor cells (CTCs) in multiple myeloma (MM): a new model to understand disease dissemination. Blood [Internet]. 2018 [cited 19];132(Suppl 1):245 LP \u2013 245. Available from: http:\/\/www.bloodjournal.org\/content\/132\/Suppl_1\/245.abstract","DOI":"10.1182\/blood-2018-99-113331"},{"key":"1897_CR62","doi-asserted-by":"crossref","unstructured":"Lohr JG, Kim S, Gould J, Knoechel B, Drier Y, Cotton MJ, et al. (2016) Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Sci Transl Med [Internet]. [cited 2019 Aug 20];8(363):363ra147. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27807282","DOI":"10.1126\/scitranslmed.aac7037"},{"issue":"22","key":"1897_CR63","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1182\/blood-2013-06-510453","volume":"122","author":"B Paiva","year":"2013","unstructured":"Paiva B, Paino T, Sayagues J, Garayoa M, San-segundo L, Mota I et al (2013) Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood. 122(22):3591\u20133599","journal-title":"Blood."},{"key":"1897_CR64","doi-asserted-by":"crossref","unstructured":"Li J, Wang N, Tesfaluul N, Gao X, Liu S, Yue B, (2017) Prognostic value of circulating plasma cells in patients with multiple myeloma: a meta-analysis. PLoS One [Internet]. [cited 2019 Aug 20];12(7):e0181447. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28704521","DOI":"10.1371\/journal.pone.0181447"},{"key":"1897_CR65","doi-asserted-by":"crossref","unstructured":"Nowakowski GS, Witzig TE, Dingli D, Tracz MJ, Gertz MA, Lacy MQ, et al. (2005) Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood [Internet]. [cited 2019 Aug 19];106(7):2276\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15961515","DOI":"10.1182\/blood-2005-05-1858"},{"key":"1897_CR66","doi-asserted-by":"crossref","unstructured":"Gonsalves WI, Morice WG, Rajkumar V, Gupta V, Timm MM, Dispenzieri A, et al. (2014) Quantification of clonal circulating plasma cells in relapsed multiple myeloma. Br J Haematol [Internet]. [cited 2019 Aug 19];167(4):500\u20135. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25113422","DOI":"10.1111\/bjh.13067"},{"key":"1897_CR67","doi-asserted-by":"crossref","unstructured":"Bianchi G, Richardson PG, Anderson KC (2015) Title Page Bianchi et al. Promising therapies in myeloma promising therapies in multiple myeloma. Blood First Ed Pap [Internet]. Available from: www.bloodjournal.org","DOI":"10.1182\/blood-2015-03-575365"},{"key":"1897_CR68","doi-asserted-by":"crossref","unstructured":"Mithraprabhu S, Spencer A (2017) Circulating tumour DNA analysis in multiple myeloma. Vol. 8, Oncotarget. Impact Journals LLC; p. 90610\u20131","DOI":"10.18632\/oncotarget.21595"},{"issue":"6","key":"1897_CR69","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.3324\/haematol.2017.184358","volume":"103","author":"B Gerber","year":"2018","unstructured":"Gerber B, Manzoni M, Spina V, Bruscaggin A, Lionetti M, Fabris S, Barbieri M, Ciceri G, Pompa A, Forestieri G, Lerch E, Servida P, Bertoni F, Zucca E, Ghielmini M, Cortelezzi A, Cavalli F, Stussi G, Baldini L, Rossi D, Neri A (2018 Jun) Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias. Haematologica. 103(6):e245\u2013e248","journal-title":"Haematologica."},{"issue":"7","key":"1897_CR70","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3324\/haematol.2016.160564","volume":"102","author":"EH Rustad","year":"2017","unstructured":"Rustad EH, Coward E, Skyt\u00f8en ER, Misund K, Holien T, Standal T, B\u00f8rset M, Beisvag V, Myklebost O, Meza-Zepeda LA, Dai HY, Sundan A, Waage A (2017 Jul) Monitoring multiple myeloma by quantification of recurrent mutations in serum. Haematologica. 102(7):1266\u20131272","journal-title":"Haematologica."},{"key":"1897_CR71","doi-asserted-by":"publisher","first-page":"15086","DOI":"10.1038\/ncomms15086","volume":"8","author":"O Kis","year":"2017","unstructured":"Kis O, Kaedbey R, Chow S, Danesh A, Dowar M, Li T et al (2017 May) Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates. Nat Commun 8:15086","journal-title":"Nat Commun"},{"key":"1897_CR72","doi-asserted-by":"crossref","unstructured":"Weinhold N, Chavan SS, Heuck C, Stephens OW, Tytarenko R, Bauer M et al (2015) High risk multiple myeloma demonstrates marked spatial genomic heterogeneity between focal lesions and random bone marrow; implications for targeted therapy and treatment resistance. Blood.:126(23)","DOI":"10.1182\/blood.V126.23.20.20"},{"issue":"8","key":"1897_CR73","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/annonc\/mdp006","volume":"20","author":"S Hohaus","year":"2009","unstructured":"Hohaus S, Giachelia M, Massini G, Mansueto G, Vannata B, Bozzoli V, Criscuolo M, D'Al\u00f2 F, Martini M, Larocca LM, Voso MT, Leone G (2009 May) Cell-free circulating DNA in Hodgkin\u2019s and non-Hodgkin\u2019s lymphomas. Ann Oncol 20(8):1408\u20131413","journal-title":"Ann Oncol"},{"issue":"9","key":"1897_CR74","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00277-009-0698-6","volume":"88","author":"AK Schwarz","year":"2009","unstructured":"Schwarz AK, Stanulla M, Cario G, Flohr T, Sutton R, M\u00f6ricke A, Anker P, Stroun M, Welte K, Bartram CR, Schrappe M, Schrauder A (2009) Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia. Ann Hematol 88(9):897\u2013905","journal-title":"Ann Hematol"},{"key":"1897_CR75","unstructured":"Leon SA, Shapiro B, Sklaroff DM, Yaros MJ (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37(3):646 LP \u2013 650"},{"key":"1897_CR76","doi-asserted-by":"crossref","unstructured":"Oberle A, Brandt A, Voigtlaender M, Thiele B, Radloff J, Schulenkorf A, et al. (2017) Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA. Haematologica. 102(6):1105 LP \u2013 1111","DOI":"10.3324\/haematol.2016.161414"},{"issue":"1","key":"1897_CR77","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1053\/j.seminhematol.2018.03.002","volume":"55","author":"TJ Pugh","year":"2018","unstructured":"Pugh TJ (2018) Circulating tumour DNA for detecting minimal residual disease in multiple myeloma. Semin Hematol 55(1):38\u201340","journal-title":"Semin Hematol"},{"key":"1897_CR78","doi-asserted-by":"crossref","unstructured":"Mazzotti C, Buisson L, Maheo S, Perrot A, Chretien M-L, Leleu X, et al. (2018) Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Adv. 2(21):2811 LP \u2013 2813","DOI":"10.1182\/bloodadvances.2018025197"},{"key":"1897_CR79","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C et al (2017 Feb) Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 17:223","journal-title":"Nat Rev Cancer"},{"key":"1897_CR80","doi-asserted-by":"crossref","unstructured":"Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, et al. (2010) The microRNA spectrum in 12 body fluids; Available from: http:\/\/www.clinchem.org\/content\/","DOI":"10.1373\/clinchem.2010.147405"},{"key":"1897_CR81","doi-asserted-by":"crossref","unstructured":"Wang K, Yuan Y, Cho JH, McClarty S, Baxter D, Galas DJ (2012) Comparing the MicroRNA spectrum between serum and plasma. PLoS One","DOI":"10.1371\/journal.pone.0041561"},{"key":"1897_CR82","doi-asserted-by":"crossref","unstructured":"Mittelbrunn M, Guti\u00e9rrez-V\u00e1zquez C, Villarroya-Beltri C, Gonz\u00e1lez S, S\u00e1nchez-Cabo F, Gonz\u00e1lez M\u00c1, et al (2011) Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun","DOI":"10.1038\/ncomms1285"},{"key":"1897_CR83","doi-asserted-by":"crossref","unstructured":"Jaiswal R, Luk F, Gong J, Mathys JM, Grau GER, Bebawy M (2012) Microparticle conferred microRNA profiles - implications in the transfer and dominance of cancer traits. Mol Cancer","DOI":"10.1186\/1476-4598-11-37"},{"key":"1897_CR84","doi-asserted-by":"crossref","unstructured":"Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Vol. 105, PNAS","DOI":"10.1073\/pnas.0804549105"},{"key":"1897_CR85","doi-asserted-by":"crossref","unstructured":"Turchinovich A, Weiz L, Burwinkel B (2012) Extracellular miRNAs: the mystery of their origin and function. Trends Biochem Sci","DOI":"10.1016\/j.tibs.2012.08.003"},{"key":"1897_CR86","doi-asserted-by":"crossref","unstructured":"Ohshima K, Inoue K, Fujiwara A, Hatakeyama K, Kanto K, Watanabe Y et al (2010) Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS One","DOI":"10.1371\/journal.pone.0013247"},{"key":"1897_CR87","doi-asserted-by":"crossref","unstructured":"Pichiorri F, Suh S-S, Ladetto M, Kuehl M, Palumbo T, Drandi D, et al (2008) MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci","DOI":"10.1073\/pnas.0806202105"},{"key":"1897_CR88","doi-asserted-by":"crossref","unstructured":"Sevcikova S, Kubiczkova L, Sedlarikova L, Slaby O, Hajek R. (2013) Serum miR-29a as a marker of multiple myeloma. Leuk Lymphoma [Internet]. [cited 2019 Jul 18];54(1):189\u201391. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22712836","DOI":"10.3109\/10428194.2012.704030"},{"key":"1897_CR89","doi-asserted-by":"crossref","unstructured":"Yu J, Qiu X, Shen X, Shi W, Wu X, Gu G, et al. (2014) miR-202 expression concentration and its clinical significance in the serum of multiple myeloma patients. Ann Clin Biochem","DOI":"10.1177\/0004563213501155"},{"key":"1897_CR90","doi-asserted-by":"crossref","unstructured":"Huang JJ, Yu J, Li JY, Liu YT, Zhong RQ (2012) Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma. Med Oncol","DOI":"10.1007\/s12032-012-0210-3"},{"key":"1897_CR91","doi-asserted-by":"crossref","unstructured":"Yoshizawa S, Ohyashiki JH, Ohyashiki M, Umezu T, Suzuki K, Inagaki A, et al. (2012) Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer J","DOI":"10.1038\/bcj.2011.51"},{"key":"1897_CR92","doi-asserted-by":"crossref","unstructured":"Jones CI, Zabolotskaya MV, King AJ, Stewart HJS, Horne GA, Chevassut TJ et al (2012) Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer","DOI":"10.1038\/bjc.2012.525"},{"key":"1897_CR93","doi-asserted-by":"crossref","unstructured":"Kubiczkova L, Kryukov F, Slaby O, Dementyeva E, Jarkovsky J, Nekvindova J, et al (2014) Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica","DOI":"10.3324\/haematol.2013.093500"},{"key":"1897_CR94","doi-asserted-by":"crossref","unstructured":"Hao M, Zang M, Wendlandt E, Xu Y, An G, Gong D, et al. (2015) Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. Int J Cancer","DOI":"10.1002\/ijc.29199"},{"key":"1897_CR95","doi-asserted-by":"crossref","unstructured":"Qu X, Zhao M, Wu S, Yu W, Xu J, Xu J, et al. (2014) Circulating microRNA 483-5p as a novel biomarker for diagnosis survival prediction in multiple myeloma. Med Oncol","DOI":"10.1007\/s12032-014-0219-x"},{"key":"1897_CR96","doi-asserted-by":"crossref","unstructured":"Navarro A, D\u00edaz T, Tovar N, Pedrosa F, Tejero R, Cibeira MT, et al (2015) A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. Oncotarget","DOI":"10.18632\/oncotarget.2761"},{"key":"1897_CR97","doi-asserted-by":"crossref","unstructured":"Rocci A, Hofmeister CC, Geyer S, Stiff A, Gambella M, Cascione L, et al (2014) Circulating miRNA markers show promise as new prognosticators for multiple myeloma. Leukemia","DOI":"10.1038\/leu.2014.155"},{"key":"1897_CR98","doi-asserted-by":"crossref","unstructured":"Chen L, Li C, Zhang R, Gao X, Qu X, Zhao M, et al. (2011) MiR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. Cancer Lett","DOI":"10.1016\/j.canlet.2011.05.017"},{"key":"1897_CR99","first-page":"6(35)","volume":"10","author":"F Li","year":"2015","unstructured":"Li F, Xu Y, Deng S, Li Z, Zou D, Yi S et al (2015) MicroRNA-15a\/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma. Oncotarget. 10:6(35)","journal-title":"Oncotarget."},{"key":"1897_CR100","doi-asserted-by":"crossref","unstructured":"Simon-Kayser B, Scoul C, Renaudin K, Jezequel P, Bouchot O, Rigaud J, et al. (2005) Molecular cloning and characterization of FBXO47, a novel gene containing an F-box domain, located in the 17q12 band deleted in papillary renal cell carcinoma. Genes Chromosom Cancer","DOI":"10.1002\/gcc.20170"},{"key":"1897_CR101","doi-asserted-by":"crossref","unstructured":"Guti\u00e9rrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las Rivas J, Ticona F V., et al. (2010) Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia","DOI":"10.1038\/leu.2009.274"},{"key":"1897_CR102","doi-asserted-by":"crossref","unstructured":"Leone E, Morelli E, Di Martino MT, Amodio N, Foresta U, Gull\u00e0 A, et al. (2013) Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res [Internet]. [cited 2019 Jul 18];19(8):2096\u2013106. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23446999","DOI":"10.1158\/1078-0432.CCR-12-3325"},{"key":"1897_CR103","doi-asserted-by":"crossref","unstructured":"Shen X, Guo Y, Qi J, Shi W, Wu X, Ni H, et al. (2016) Study on the association between miRNA-202 expression and drug sensitivity in multiple myeloma cells. Pathol Oncol Res [Internet]. [cited 2019 Jul 18];22(3):531\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26689580","DOI":"10.1007\/s12253-015-0035-4"},{"key":"1897_CR104","doi-asserted-by":"crossref","unstructured":"Zhang J, Xiao X, Liu J (2015) The role of circulating miRNAs in multiple myeloma. Sci China Life Sci [Internet]. [cited 2019 Jul 18];58(12):1262\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26607481","DOI":"10.1007\/s11427-015-4969-2"},{"key":"1897_CR105","doi-asserted-by":"crossref","unstructured":"Jung SH, Lee SE, Lee M, Kim SH, Yim SH, Kim TW, et al (2017) Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory\/relapsed multiple myeloma. Haematologica","DOI":"10.3324\/haematol.2017.168070"},{"key":"1897_CR106","doi-asserted-by":"crossref","unstructured":"Th\u00e9ry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F, Atkin-Smith GK, Ayre DC, Bach JM, Bachurski D, Baharvand H, Balaj L, Baldacchino S, Bauer NN, Baxter AA, Bebawy M, Beckham C, Bedina Zavec A, Benmoussa A, Berardi AC, Bergese P, Bielska E, Blenkiron C, Bobis-Wozowicz S, Boilard E, Boireau W, Bongiovanni A, Borr\u00e0s FE, Bosch S, Boulanger CM, Breakefield X, Breglio AM, Brennan M\u00c1, Brigstock DR, Brisson A, Broekman ML, Bromberg JF, Bryl-G\u00f3recka P, Buch S, Buck AH, Burger D, Busatto S, Buschmann D, Bussolati B, Buz\u00e1s EI, Byrd JB, Camussi G, Carter DR, Caruso S, Chamley LW, Chang YT, Chen C, Chen S, Cheng L, Chin AR, Clayton A, Clerici SP, Cocks A, Cocucci E, Coffey RJ, Cordeiro-da-Silva A, Couch Y, Coumans FA, Coyle B, Crescitelli R, Criado MF, D'Souza-Schorey C, Das S, Datta Chaudhuri A, de Candia P, de Santana EF, de Wever O, del Portillo H, Demaret T, Deville S, Devitt A, Dhondt B, di Vizio D, Dieterich LC, Dolo V, Dominguez Rubio AP, Dominici M, Dourado MR, Driedonks TA, Duarte FV, Duncan HM, Eichenberger RM, Ekstr\u00f6m K, el Andaloussi S, Elie-Caille C, Erdbr\u00fcgger U, Falc\u00f3n-P\u00e9rez JM, Fatima F, Fish JE, Flores-Bellver M, F\u00f6rs\u00f6nits A, Frelet-Barrand A, Fricke F, Fuhrmann G, Gabrielsson S, G\u00e1mez-Valero A, Gardiner C, G\u00e4rtner K, Gaudin R, Gho YS, Giebel B, Gilbert C, Gimona M, Giusti I, Goberdhan DC, G\u00f6rgens A, Gorski SM, Greening DW, Gross JC, Gualerzi A, Gupta GN, Gustafson D, Handberg A, Haraszti RA, Harrison P, Hegyesi H, Hendrix A, Hill AF, Hochberg FH, Hoffmann KF, Holder B, Holthofer H, Hosseinkhani B, Hu G, Huang Y, Huber V, Hunt S, Ibrahim AG, Ikezu T, Inal JM, Isin M, Ivanova A, Jackson HK, Jacobsen S, Jay SM, Jayachandran M, Jenster G, Jiang L, Johnson SM, Jones JC, Jong A, Jovanovic-Talisman T, Jung S, Kalluri R, Kano SI, Kaur S, Kawamura Y, Keller ET, Khamari D, Khomyakova E, Khvorova A, Kierulf P, Kim KP, Kislinger T, Klingeborn M, Klinke DJ 2nd, Kornek M, Kosanovi\u0107 MM, Kov\u00e1cs \u00c1F, Kr\u00e4mer-Albers EM, Krasemann S, Krause M, Kurochkin IV, Kusuma GD, Kuypers S, Laitinen S, Langevin SM, Languino LR, Lannigan J, L\u00e4sser C, Laurent LC, Lavieu G, L\u00e1zaro-Ib\u00e1\u00f1ez E, le Lay S, Lee MS, Lee YXF, Lemos DS, Lenassi M, Leszczynska A, Li IT, Liao K, Libregts SF, Ligeti E, Lim R, Lim SK, Lin\u0113 A, Linnemannst\u00f6ns K, Llorente A, Lombard CA, Lorenowicz MJ, L\u00f6rincz \u00c1M, L\u00f6tvall J, Lovett J, Lowry MC, Loyer X, Lu Q, Lukomska B, Lunavat TR, Maas SL, Malhi H, Marcilla A, Mariani J, Mariscal J, Martens-Uzunova ES, Martin-Jaular L, Martinez MC, Martins VR, Mathieu M, Mathivanan S, Maugeri M, McGinnis L, McVey M, Meckes DG Jr, Meehan KL, Mertens I, Minciacchi VR, M\u00f6ller A, M\u00f8ller J\u00f8rgensen M, Morales-Kastresana A, Morhayim J, Mullier F, Muraca M, Musante L, Mussack V, Muth DC, Myburgh KH, Najrana T, Nawaz M, Nazarenko I, Nejsum P, Neri C, Neri T, Nieuwland R, Nimrichter L, Nolan JP, Nolte-'t Hoen EN, Noren Hooten N, O'Driscoll L, O'Grady T, O'Loghlen A, Ochiya T, Olivier M, Ortiz A, Ortiz LA, Osteikoetxea X, \u00d8stergaard O, Ostrowski M, Park J, Pegtel DM, Peinado H, Perut F, Pfaffl MW, Phinney DG, Pieters BC, Pink RC, Pisetsky DS, Pogge von Strandmann E, Polakovicova I, Poon IK, Powell BH, Prada I, Pulliam L, Quesenberry P, Radeghieri A, Raffai RL, Raimondo S, Rak J, Ramirez MI, Raposo G, Rayyan MS, Regev-Rudzki N, Ricklefs FL, Robbins PD, Roberts DD, Rodrigues SC, Rohde E, Rome S, Rouschop KM, Rughetti A, Russell AE, Sa\u00e1 P, Sahoo S, Salas-Huenuleo E, S\u00e1nchez C, Saugstad JA, Saul MJ, Schiffelers RM, Schneider R, Sch\u00f8yen TH, Scott A, Shahaj E, Sharma S, Shatnyeva O, Shekari F, Shelke GV, Shetty AK, Shiba K, Siljander PR, Silva AM, Skowronek A, Snyder OL 2nd, Soares RP, S\u00f3dar BW, Soekmadji C, Sotillo J, Stahl PD, Stoorvogel W, Stott SL, Strasser EF, Swift S, Tahara H, Tewari M, Timms K, Tiwari S, Tixeira R, Tkach M, Toh WS, Tomasini R, Torrecilhas AC, Tosar JP, Toxavidis V, Urbanelli L, Vader P, van Balkom B, van der Grein S, van Deun J, van Herwijnen M, van Keuren-Jensen K, van Niel G, van Royen M, van Wijnen A, Vasconcelos MH, Vechetti IJ Jr, Veit TD, Vella LJ, Velot \u00c9, Verweij FJ, Vestad B, Vi\u00f1as JL, Visnovitz T, Vukman KV, Wahlgren J, Watson DC, Wauben MH, Weaver A, Webber JP, Weber V, Wehman AM, Weiss DJ, Welsh JA, Wendt S, Wheelock AM, Wiener Z, Witte L, Wolfram J, Xagorari A, Xander P, Xu J, Yan X, Y\u00e1\u00f1ez-M\u00f3 M, Yin H, Yuana Y, Zappulli V, Zarubova J, \u017d\u0117kas V, Zhang JY, Zhao Z, Zheng L, Zheutlin AR, Zickler AM, Zimmermann P, Zivkovic AM, Zocco D, Zuba-Surma EK (2018 Dec) Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 7(1):1535750","DOI":"10.1080\/20013078.2018.1535750"},{"key":"1897_CR107","doi-asserted-by":"crossref","unstructured":"Maia J, Caja S, Carolina M, Moraes S, Couto N, Costa-silva B (2018) Exosome-based cell-cell communication in the tumor microenvironment; 6(February):1\u201319","DOI":"10.3389\/fcell.2018.00018"},{"key":"1897_CR108","doi-asserted-by":"crossref","unstructured":"Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, et al. (2013) BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest","DOI":"10.1172\/JCI66517"},{"key":"1897_CR109","doi-asserted-by":"crossref","unstructured":"Wang J, De Veirman K, De Beule N, Maes K, De Bruyne E, Valckenborgh E Van, et al (2015) The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells. Oncotarget. 6(41)","DOI":"10.18632\/oncotarget.6083"},{"key":"1897_CR110","doi-asserted-by":"crossref","unstructured":"Faict S, Muller J, De Veirman K, De Bruyne E, Maes K, Vrancken L, et al. (2018) Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts. Blood Cancer J.","DOI":"10.1038\/s41408-018-0139-7"},{"key":"1897_CR111","doi-asserted-by":"crossref","unstructured":"Raimondi L, De Luca A, Amodio N, Manno M, Raccosta S, Taverna S, et al. (2015) Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation. Oncotarget. 6(15)","DOI":"10.18632\/oncotarget.3830"},{"key":"1897_CR112","doi-asserted-by":"crossref","unstructured":"Guo HM, Sun L, Yang L, Liu XJ, Nie ZY, Luo JM (2018) Microvesicles shed from bortezomib-treated or lenalidomide-treated human myeloma cells inhibit angiogenesis in vitro. Oncol Rep","DOI":"10.3892\/or.2018.6395"},{"key":"1897_CR113","doi-asserted-by":"crossref","unstructured":"Zarfati M, Avivi I, Brenner B, Katz T, Aharon A (2018) Extracellular vesicles of multiple myeloma cells utilize the proteasome inhibitor mechanism to moderate endothelial angiogenesis. Angiogenesis","DOI":"10.1007\/s10456-018-9649-y"},{"key":"1897_CR114","doi-asserted-by":"crossref","unstructured":"Zarfati M, Avivi I, Brenner B, Katz T, Aharon A (2018) Extracellular vesicles of multiple myeloma cells utilize the proteasome inhibitor mechanism to moderate endothelial angiogenesis. Angiogenesis.;0(0):0","DOI":"10.1007\/s10456-018-9649-y"},{"key":"1897_CR115","doi-asserted-by":"crossref","unstructured":"Nielsen Id T, Kristensen SR, Gregersen H, Teodorescu EM, Christiansen G, Pedersenid S (2019) Extracellular vesicle-associated procoagulant phospholipid and tissue factor activity in multiple myeloma","DOI":"10.1371\/journal.pone.0210835"},{"issue":"17","key":"1897_CR116","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1182\/blood-2016-09-742296","volume":"129","author":"S Manier","year":"2017","unstructured":"Manier S, Liu CJ, Avet-Loiseau H, Park J, Shi J, Campigotto F, Salem KZ, Huynh D, Glavey SV, Rivotto B, Sacco A, Roccaro AM, Bouyssou J, Minvielle S, Moreau P, Facon T, Leleu X, Weller E, Trippa L, Ghobrial IM (2017) Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood. 129(17):2429\u20132436","journal-title":"Blood."},{"key":"1897_CR117","doi-asserted-by":"crossref","unstructured":"Zhang L, Pan L, Xiang B, Zhu H, Wu Y, Chen M Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma. 7(21)","DOI":"10.18632\/oncotarget.9021"},{"key":"1897_CR118","doi-asserted-by":"crossref","unstructured":"Wang J, Hendrix A, Hernot S, Lemaire M, De Bruyne E, Valckenborgh E Van, et al (2014) Bone marrow stromal cell\u2013derived exosomes as communicators in drug resistance in multiple myeloma cells;124(4):555\u201366","DOI":"10.1182\/blood-2014-03-562439"},{"key":"1897_CR119","first-page":"9","volume":"8","author":"S Keller","year":"2011","unstructured":"Keller S, Ridinger J, Rupp AK, Janssen JWG, Altevogt P (2011) Body fluid derived exosomes as a novel template for clinical diagnostics. J Transl Med 8:9","journal-title":"J Transl Med"},{"key":"1897_CR120","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/j.clml.2015.07.183","volume":"15","author":"S Manier","year":"2015","unstructured":"Manier S, Avet-Loiseau H, Campigotto F, Shi J, Roccaro AM, Minvielle S et al (2015) Circulating exosomal microRNAs are critical prognostic markers independent of cytogenetics and international staging system in multiple myeloma. Clin Lymphoma Myeloma Leuk 15:e47\u2013e48","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1897_CR121","doi-asserted-by":"crossref","unstructured":"Jeppesen DK, Fenix AM, Franklin JL, Higginbotham JN, Zhang Q, Zimmerman LJ, et al. Reassessment of exosome composition. Cell. 2019 Apr 4;177(2):428\u2013445.e18","DOI":"10.1016\/j.cell.2019.02.029"},{"key":"1897_CR122","doi-asserted-by":"crossref","unstructured":"Ferreira BV, Lucio P, Neves M, Parreira A, Costa-Silva B, Joao C (2018) Characterization of circulating and bone marrow derived exosomes in multiple myeloma patients. Blood. 132(Suppl 1):3172 LP \u2013 3172","DOI":"10.1182\/blood-2018-99-117656"},{"key":"1897_CR123","doi-asserted-by":"crossref","unstructured":"Best MG, Wesseling P, Wurdinger T (2018) Tumor-educated platelets as a noninvasive biomarker source for cancer detection and progression monitoring. Vol. 78, Cancer Research. American Association for Cancer Research Inc.; p. 3407\u201312","DOI":"10.1158\/0008-5472.CAN-18-0887"},{"issue":"10","key":"1897_CR124","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1158\/1078-0432.CCR-17-2003","volume":"24","author":"S Takagi","year":"2018","unstructured":"Takagi S, Tsukamoto S, Park J, Johnson KE, Kawano Y, Moschetta M et al (2018) Platelets enhance multiple myeloma progression via il-1b upregulation. Clin Cancer Res 24(10):2430\u20132439","journal-title":"Clin Cancer Res"}],"updated-by":[{"DOI":"10.1007\/s00109-024-02500-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000}}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-020-01897-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-020-01897-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-020-01897-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T16:08:13Z","timestamp":1731427693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-020-01897-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":124,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1897"],"URL":"https:\/\/doi.org\/10.1007\/s00109-020-01897-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00109-024-02500-1","asserted-by":"object"}]},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"20 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00109-024-02500-1","URL":"https:\/\/doi.org\/10.1007\/s00109-024-02500-1","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}